Botulinum toxin A as treatment for drooling saliva in PD.
The authors evaluated intraparotid injections of botulinum toxin A in reducing salivary secretions and drooling in nine patients with PD. There was a marked objective reduction in secretion, and two thirds of the patients had subjective improvement in drooling. No side effects were observed. The authors conclude that botulinum toxin A promises to be a simple and effective treatment for the common problem of drooling saliva in chronic neurologic disease.
Pal
P K
PK
Neurodegenerative Disorders Centre, UBC Hospital, Vancouver, BC, Canada.
Calne
D B
DB
Calne
S
S
Tsui
J K
JK
D000368:Aged; D000369:Aged, 80 and over; D019274:Botulinum Toxins, Type A / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007267:Injections; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000150:complications*; D010306:Parotid Gland / Q000187:drug effects / Q000378:metabolism; D012463:Saliva / Q000187:drug effects / Q000378:metabolism; D012798:Sialorrhea / Q000188:drug therapy* / Q000209:etiology*; D016896:Treatment Outcome
D019274:Botulinum Toxins, Type A